pyradine,? thymine.f chlorouracil," a I5N analogue of 5-FU,1l bromouracil.P and phenanthrene-s have all been suggested as internal or external standards for the chromatographic assay of 5-FU. Many of these are not good internal standards for the assay of 5-FU. For example, different mobile phases are used for the elution of thymidine and 5-FU from the HPLC column." Also, in our hands, the extraction of 5-fluorocytosine is more sensitive to salt saturation of plasma than is that of 5-FU. In contrast, tritiated 5-FU. the I5N analogue of 5-FU. and chIoro-and bromouracil are all good internal standards for 5-FU assay.
A rapid high-performance liquid chromatographic method for quantitation of 5-fluorouracil in plasma after continuous intravenous infusion D C SAMPSON·, R M FOXt, M H N TATTERSALLt, AND W J HENSLEY· From the • Department of Biochemistry, Royal Prince Alfred Hospital, Camperdown, NSW 2050, and the tLudwig Institute for Cancer Research, University ofSydney, NSW 2006, Australia SUMMARY A fast, simple, precise, high-performance liquid chromatographic method for the assay of 5-fluorouracil in plasma from humans receiving continuous intravenous infusion is described. After a single extraction, underivatised 5-fluorouracil is assayed by high-performance liquid chromatography using a variable-wavelength ultraviolet detector. After extraction of 1 m1 plasma, O'3 !Lmol/l can be assayed. The assay is reproducible and linear up to at least 40 !Lmol/l. A single determination takes 3 hours and a batch of 40 specimens can be extracted and assayed in 4 working hours if automated equipment is used, enabling injections and calculations to be done overnight.
The antimetabolite 5-fluorouracil (5-FU) is widely used in cancer chemotherapy. Some centres have attempted to correlate both therapeutic response and toxicity with plasma levels of 5-FU.I Due to the high plasma levels of 5-FU after intravenous bolus or push injection its measurement using standard extraction techniques and highperformance liquid chromatography (HPLC) has been simple. However, if 5-FU is administered by continuous intravenous infusion far lower plasma levels, albeit steady, are achieved. This has necessitated either coupled extraction, derivatisation, or complex analytical techniques. These have included HPLC methods using an ultraviolet detector-and gas chromatographic methods using a nitrogen phosphorous detector," an electron capture detector.s " or a mass spectrometer as detector. I D-13 These methods are time-consuming, and the last requires specialised equipment limiting its clinical application. To allow for the wide con-Material and methods centration range of 5-FU encountered in clinical practice plasma may be extracted in several dilutions CHEMICALS or extracted several times with different amounts of Pure 5-FU was kindly supplied by F Hoffmann-La internal standard added. Tritiated 5-FU has been Roche and Co Ltd, Basle, Switzerland. Other used as an internal standard," ' " necessitating the use halogenated uracils, including 5-bromouracil (5of a scintillation counter and the logistic require-BrU) , were obtained from Sigma Chemical Comments of counting the fractionated HPLC eluate. pany, St Louis, Missouri, USA. Extraction solvents Alternatively, 5-fluorocytosine, 3 chlorphenira-were spectroscopic grade from E Merck, Darmstadt, mtne," thymidine," 3,3-diethyl-2,4-dioxotetrahydro-Germany. All other chemicals were A R grade. 125 3 -KH 2PO 4 buffer (50 mrnol/l, pH 3). The flow rate was 0,8-1'0 ml/min (900-1200 psi) and was adjusted so that the small peak eluting just before 5-FU (peak A in Fig. 1 ) was resolved from 5-FU on the chromatogram produced by the recorder. EXTRACTION Standard plots were prepared by spiking 5-FU into normal plasma to give final concentrations ranging from 0·5 to 40 umol/l plasma; 100 fLI 5-BrU (100 fLmol/1 H 20), as an internal standard, was added to 1·0 ml of plasma. 100 fLI of 1 mol/I HCl and 10 ml of a mixture of n-propanol: diethylether (16:84) were added to the plasma sample, mixed for 30 seconds by vortexing and then centrifuged (5 min, 3000 rpm). The organic phase was dried under a stream of nitrogen in a 50°heating bath: the residue was dissolved in 200 fLI 50 mmol/l phosphate buffer, pH 11, and neutralised with 2 fLI of 1 mol/I H 2S0 4 , and 10 fLl was injected onto the HPLC column.
PATIENT MATERIALS
Daily plasma samples were obtained from patients receiving 5-FU, 2-2'25 g/m 2 daily by continuous intravenous infusion for five days, in conjunction with a study of allopurinol modulation of 5-FU toxicity.v'
Results
Representative chromatograms are shown in Figure 1 . The standard plot was linear up to 40 fLmol/1 and was reproducible for the life of the HPLC column. A fL Bondpak C18 column has been used for 5-FU analysis for more than six months.
The recovery of 5-FU spiked into normal plasma was 75% of the unextracted value (SD 4,4%, n=16). Similarly, 77 % of 5-BrU was recovered from spiked normal plasma (SD 4· 8 %, n = lO). When 5-FU was spiked into plasma of patients receiving 5-FU and the plasma was extracted and assayed, the recovery of the 5-FU spike was 105% (SD 8,2%, n=24).
Between-run precision of the assay was determined by assaying patients' plasma on several days. The coefficient of variation was 6·1 % for plasma with 5-FU concentrations ranging from 0·3 umol/l to 45 fLmol/1 (n=15).
The method described can measure 5-FU at a concentration of O·3 fLmol/1 in plasma. Extraction of a larger volume of plasma, use of a smaller volume to dissolve the final extract, or injection of a larger volume onto the HPLC column would increase this sensitivity, but in our experience this is not necessary for patient monitoring. Interference with either 5-FU or 5-BrU was not noted in either patients' or normal plasmas studied. Commonly used drugs and their metabolites did not interfere with the assay. Several unknown compounds normally occurring in plasma were encountered in the chromatograms, but these did not interfere with the 5-FU or internal standard peaks. They were not removed by additional back extraction with organic solvents. As noted by Christophidis et al., 3 one of these compounds (peak A in Fig. 1 ) elutes just before 5-FU and is completely separated from it. In extracts of plasma from patients receiving 5-FU, several unknown peaks are larger than those seen in normal plasma (Fig. 1 ). These were not removed by the back extraction recommended by Christophidis et al. 3 For this assay it is essential that blood is collected without haemolysis and that plasma is separated without red cell lysis. When duplicate specimens were collected from patients and were allowed to haemolyse, the result from the haemolysed specimen was always lower. Thus, 5-FU does not partition equally between red cells and plasma. No interference was observed when 5-FU was spiked into lipaemic or icteric plasma before analysis, although none of the specimens collected from patients receiving 5-FU was lipaemic or icteric.
The data module on the HPLC system provides a chromatogram and a table giving each peak together with its retention time, identification (if identified), and peak area. For calibrated peaks, such as 5-FU in this case, the result in fLmol/1 is also printed out from a calculation of the 5-FU peak area relative to that of the internal standard peak area. The use of an autoinjector enables samples to be injected overnight unattended. The model TWA autoinjector will take 48 injection vials so that up to 40 samples can be run with eight standards and/or quality control specimens. Samples are usually extracted in the afternoon and injected overnight so that results are ready in the morning. A single determination takes about 3 hours for extraction and injection of the unknown, three standards, and high and low quality control specimens.
The clinical results of this study have been reported elsewhere.P Plasma 5-FU levels were determined on blood samples collected daily from 13 patients receiving five-day continuous infusions of 5-FU at 2-2·25 g/m 2 • Plasma levels of 5-FU varied from patient to patient and fluctuated from day to day in each individual patient. The mean 5-FU level for all samples was 5· 8 fLmol/I, ranging widely from the limit of detection (0' 3 fLmol/l) to 45 !J.mol/1. Increased toxicity was manifest in patients with higher 5-FU levels. The distribution of plasma 5-FU levels was skewed to the left, 83 % of samples having a level less than 8' 2 !J.mo1/l (mean 3·3 umol/l, ranging from the limit of detection to 8' 2 fLmol/I); 17%of samples had a level greater than 9·9 !J.mol/l (mean 18·0 fLmol/I, range 9·9 to 45 fLmol/I). This implication of two populations should be investigated further.
The levels obtained in this study are approximately twice the concentration of 5-FU in plasma reported by Hillcoat et aU They gave 5-FU by continuous 24-hour infusion at a dose of 1'2 g/m 2/24 hand measured 5-FU levels in plasma by a gas chromatographic-mass spectrometric method. The availability of our simple HPLC assay method may allow more detailed clinical pharmacological studies in patients receiving 5-FU by continuous intravenous infusion.
